Haematology CAR-T pathway
Blood-cancer subtype, antigen target, approved product or protocol status, manufacturing, bridging therapy, toxicity readiness, and long-term follow-up are reviewed together.
Review pathwayCAR-T and oncology pathway finder
Start with the blood cancer, tumour, target, and treatment question.
Haematology CAR-T and oncology innovative therapies appear first. Use two filters to organise relevant pathways, selected centres, and comparable cost evidence; results do not determine diagnosis, eligibility, hospital acceptance, or coverage.
A filtered match is not a recommendation
Every result still requires specialist review, exact product or protocol status, hospital capability, toxicity readiness, itemised quotation, travel safety, and an accepting clinician at home.
16 pathways match·15 Selected centre profiles
01
Relevant medical pathways
Haematopoietic stem-cell transplantation
Autologous, matched allogeneic, haploidentical, unrelated-donor, and cord-blood pathways are separated by disease, graft, donor, conditioning, complications, and continuity.
Review pathwayStem-cell products and research
China-approved medicine, registered research, and unsupported commercial injections are explicitly separated by exact product, cell source, disease, oversight, risks, and access rules.
Review pathwaySatri-cel (CT041)
NMPA-approved later-line CLDN18.2-directed CAR-T for a defined advanced gastric or gastroesophageal-junction cancer population, with provider-verified commercial pathways in Shanghai and Beijing.
Review pathwayChina-origin oncology medicines
Current label, biomarker, evidence, safety, hospital supply, home-country status, and payer position require revalidation.
Review pathwayOncological surgery
Procedure, multidisciplinary team, pathology, rescue, complications, recovery, and return care are compared as one episode.
Review pathwayRadiotherapy and particle therapy
Indication, dose, fractions, image guidance, physics QA, toxicity support, and comparative value remain controlling.
Review pathwayTelitacicept for IgA nephropathy
The conditional NMPA indication, eligibility, alternatives, monitoring, supply, continuity, and funding must be confirmed for the exact case.
Review pathwayHaemophilia B gene-therapy review
Specialist eligibility, vector assessment, liver and coagulation monitoring, long-term registry, and home-haematology acceptance are mandatory.
Review pathwaySelected metabolic medicines
Approved indication, contraindications, supply, monitoring, continuity, and alternatives at home take priority over novelty.
Review pathwayJoint replacement
Implant brand, surgeon, infection control, thrombosis prevention, rehabilitation, complications, revision terms, and safe return must align.
Review pathwayBPH and kidney-stone surgery
The exact HoLEP, TURP, PCNL or other procedure, equipment, catheter, stay, reintervention, and home follow-up must match.
Review pathwayMedically indicated eye surgery
One or both eyes, lens or device, surgeon, anaesthesia, tests, complication cover, and follow-up must be defined.
Review pathwayCardiac and structural-heart care
Independent specialist review, device specification, high-acuity rescue, rehabilitation, anticoagulation, and home-cardiology acceptance are required.
Review pathwayNeurosurgery and device pathways
Diagnosis, imaging, multidisciplinary review, ICU rescue, device compatibility, programming, rehabilitation, and long-term follow-up are inseparable.
Review pathwayReconstructive and maxillofacial surgery
Function, cancer status where relevant, airway, implants, dental planning, rehabilitation, staged procedures, and revision responsibility must be documented.
Review pathway15Selected centre profiles
Compare matching centres02
Cost evidence and quotation gates
| Defined episode | Mainland China | United Kingdom | United States | Evidence basis |
|---|---|---|---|---|
| Robot-assisted radical prostatectomyIndicative evidence only | CNY 60,000–80,000 planning range; domestic median CNY 67,380.5 | GBP 20,000–30,000 private estimate | USD 16,056–27,037 participating-provider cash purchase | Different bundles; written hospital quote required |
| Partial nephrectomyIndicative evidence only | CNY 68,406.7–76,922.5 domestic robotic cohort | From GBP 11,000 provider example | USD 14,170–25,274 participating-provider cash purchase | Confirm partial/radical and robotic/laparoscopic definitions |
| Colorectal resectionIndicative evidence only | CNY 32,515.61–49,210.59 domestic inpatient evidence | GBP 17,350–28,140 private package examples | USD 7,882–40,293 participating-provider cash purchase | Site, stoma, professional fees, and complications differ |
| Partial liver resectionIndicative evidence only | CNY 63,929–94,356 domestic DRG-era evidence | From GBP 30,980 hospital package | USD 21,569–28,019 participating-provider cash purchase | Extent, cirrhosis, ICU, and fee inclusions require confirmation |
| Five-fraction prostate SBRTMethodology-led comparison only | CNY 37,193–38,251 official provincial component example | GBP 12,000–16,000 private estimate | USD 16,375–24,895 calculated delivery purchases | Different billing units; planning may be additional |
| Proton-therapy courseIndication-specific comparison only | CNY 170,000 domestic-system cap to approx. CNY 300,000 reported imported-system course | GBP 27,000–48,000 private examples | USD 25,000–100,000+ provider-reported range | Indication, fractions, ancillaries, and comparative value vary |
| Total knee or hip replacementQuotation-only pathway | Current itemised hospital quote required | Matching private self-pay quote required | Matching cash or payer quote required | Align implant brand, surgeon, length of stay, rehabilitation, complications, and revision terms |
| BPH or kidney-stone surgeryQuotation-only pathway | Current itemised hospital quote required | Matching private self-pay quote required | Matching cash or payer quote required | Align HoLEP, TURP, PCNL or other exact procedure, equipment, catheter, stay, and reintervention |
| Cataract or medically indicated ophthalmic surgeryQuotation-only pathway | Current itemised hospital quote required | Matching private self-pay quote required | Matching cash or payer quote required | Align one or both eyes, lens or device brand, surgeon, anaesthesia, tests, and follow-up |
| Bariatric or benign gynaecological surgeryQuotation-only pathway | Current itemised hospital quote required | Matching private self-pay quote required | Matching cash or payer quote required | Align exact operation, preoperative programme, device, pathology, stay, complications, nutrition, and follow-up |